Bridge City Capital LLC Has $2.92 Million Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Bridge City Capital LLC increased its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 0.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 57,892 shares of the biotechnology company’s stock after buying an additional 518 shares during the period. Bridge City Capital LLC’s holdings in Corcept Therapeutics were worth $2,917,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of CORT. Kestra Investment Management LLC acquired a new position in Corcept Therapeutics during the 4th quarter worth $27,000. USA Financial Formulas acquired a new position in shares of Corcept Therapeutics during the 4th quarter worth about $54,000. Newbridge Financial Services Group Inc. bought a new stake in Corcept Therapeutics during the 4th quarter valued at approximately $58,000. Principal Securities Inc. grew its holdings in Corcept Therapeutics by 63.6% in the 4th quarter. Principal Securities Inc. now owns 1,243 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 483 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new position in Corcept Therapeutics in the 4th quarter worth approximately $69,000. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $50.54, for a total value of $111,188.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Sean Maduck sold 20,000 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $50.39, for a total value of $1,007,800.00. Following the transaction, the insider now owns 85,318 shares of the company’s stock, valued at $4,299,174.02. The trade was a 18.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 45,627 shares of company stock valued at $2,557,674 in the last 90 days. 20.50% of the stock is owned by corporate insiders.

Corcept Therapeutics Trading Up 1.9 %

Shares of CORT stock opened at $58.66 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The firm has a fifty day moving average of $61.49 and a 200-day moving average of $53.81. Corcept Therapeutics Incorporated has a 52-week low of $20.84 and a 52-week high of $75.00. The stock has a market cap of $6.19 billion, a price-to-earnings ratio of 46.56 and a beta of 0.61.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.11). Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The business had revenue of $181.89 million for the quarter, compared to the consensus estimate of $200.12 million. On average, equities research analysts forecast that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on CORT. HC Wainwright reaffirmed a “buy” rating and set a $115.00 target price on shares of Corcept Therapeutics in a research report on Thursday, February 27th. Canaccord Genuity Group upped their price objective on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, January 30th. StockNews.com downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. Finally, Piper Sandler upped their price target on Corcept Therapeutics from $67.00 to $78.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $99.75.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.